Effect of Evolocumab on Non‐High‐Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies

Background Dyslipidemia guidelines recommend non‐high‐density lipoprotein cholesterol (non‐HDL‐C) and apolipoprotein B (ApoB) as additional targets of therapy and consider lipoprotein(a) a significant cardiovascular risk marker. The current analysis evaluates the effects of evolocumab on these param...

Description complète

Détails bibliographiques

Auteurs principaux:	Peter P. Toth, Steven R. Jones, Maria Laura Monsalvo, Mary Elliott‐Davey, J. Antonio G. López, Maciej Banach
Format:	Artigo
Langue:	Inglês
Publié:	Wiley 2020-03-01
Collection:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Sujets:	apolipoprotein lipids and lipoproteins low‐density lipoprotein cholesterol
Accès en ligne:	https://www.ahajournals.org/doi/10.1161/JAHA.119.014129
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!